Effect of Intra-Stromal Bevacizumab on Corneal Vascularization

Purpose: To study the effect of Intra-stromal Bevacizumab on corneal vascularization. Study Design: Quasi experimental study. Place and Duration Study: Outpatient department Combined Military Hospital, Multan from April 2022 to August 2022. Methods: Thirty patients were recruited through non-probability, convenience sampling technique. Ethical approval was taken Institutional Review Board. Complete ocular examination performed by a consultant ophthalmologist with neovascularization included in Area vascularization measured slit lamp. After taking all aseptic measures administering anesthetic eye drops, administered 0.2 ml (2.5 mg/0.1 mL) (Avastin, Roche) using an ophthalmic microscope. The patient then called for follow up after 4 weeks grade checked lamp examination. Data analysis doneusing SPSS version 25. Results: Mean age 43.4 ± 13.7 years (range 25 72 years). Male female ratio 2:3. There significant decrease area 2.78mm 0.30 2.50mm 0.27 (p = 0.0003). mean change 10.07%. Two had sub-conjunctival hemorrhage which settled over due course time. Conclusion: resulted reduction vascularized cornea minimal side effects indicating that intra-stromal is effective safe modality treatment neovascularization.